ECOR News & Events

electroCore published clinical findings in JAMA Network Open from a cluster randomized trial evaluating its Quell device added to outpatient physical therapy, or PT, in 384 fibromyalgia patients. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, with statistically significant improvements also seen in resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact. Benefits were observed within 30 days and sustained for up to six months, with 81% of respondents finding Quell helpful and 55% continuing daily use.

The company said, "For the full year of 2026, the Company is reiterating revenue guidance of approximately 30% annual revenue growth over 2025."

Reports Q1 revenue $9.58M, consensus $9.01M. "Our first quarter results reflect what we believe is a meaningful inflection point for electroCore," said Joshua Lev, Interim President and Chief Financial Officer of electroCore. "Quarterly revenue of $9.6 million was our highest ever and was accomplished with 87% gross profit margin. Net loss for the quarter was $5.3 million, however, after removing items such as non-recurring expenses associated with the leadership changes, we exhibited a 24% year-over-year improvement in adjusted EBITDA loss, demonstrating the operating leverage we expect to see as our platform scales. Each of our prescription channels - gammaCore in the VA and our Quell Fibromyalgia franchise acquired from NeuroMetrix, Inc. ("NURO") last year - is contributing meaningfully, while our Truvaga consumer wellness brand continues to grow. With the leadership transition substantially behind us and Michael Fox on board to accelerate revenue growth, we believe we are well-positioned to execute against our full-year guidance."